See more : TOYA S.A. (TOA.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Philip Morris International Inc. (PM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Philip Morris International Inc., a leading company in the Tobacco industry within the Consumer Defensive sector.
You may be interested
- Sabre Corporation (SABR) Income Statement Analysis – Financial Results
- Dogu Aras Enerji Yatirimlari AS (ARASE.IS) Income Statement Analysis – Financial Results
- TechCom, Inc. (TCRI) Income Statement Analysis – Financial Results
- Yangmei Chemical Co.,Ltd (600691.SS) Income Statement Analysis – Financial Results
- Span Divergent Limited (SDL.BO) Income Statement Analysis – Financial Results
Philip Morris International Inc. (PM)
About Philip Morris International Inc.
Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.17B | 31.76B | 31.41B | 28.69B | 29.81B | 29.63B | 28.75B | 26.69B | 26.79B | 29.77B | 31.22B | 31.38B | 31.10B | 27.21B | 25.04B | 25.71B | 22.80B | 48.26B | 45.29B | 33.39B | 8.10B |
| Cost of Revenue | 12.89B | 11.23B | 10.03B | 9.57B | 10.51B | 10.76B | 10.43B | 9.39B | 9.37B | 10.44B | 10.41B | 10.37B | 10.68B | 9.71B | 9.02B | 9.33B | 8.72B | 35.62B | 32.92B | 23.82B | 2.81B |
| Gross Profit | 22.28B | 20.53B | 21.38B | 19.13B | 19.29B | 18.87B | 18.32B | 17.29B | 17.43B | 19.33B | 20.81B | 21.00B | 20.42B | 17.50B | 16.01B | 16.38B | 14.08B | 12.64B | 12.37B | 9.57B | 5.30B |
| Gross Profit Ratio | 63.35% | 64.65% | 68.06% | 66.65% | 64.73% | 63.69% | 63.71% | 64.81% | 65.05% | 64.94% | 66.65% | 66.94% | 65.66% | 64.30% | 63.96% | 63.71% | 61.75% | 26.19% | 27.31% | 28.66% | 65.36% |
| Research & Development | 709.00M | 642.00M | 617.00M | 495.00M | 465.00M | 383.00M | 453.00M | 429.00M | 423.00M | 433.00M | 449.00M | 415.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 10.11B | 8.14B | 8.52B | 7.48B | 8.78B | 7.45B | 6.73B | 6.41B | 6.66B | 7.00B | 6.89B | 6.98B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | -148.00M | 8.30B | 7.38B | 8.70B | 7.41B | 6.73B | 6.41B | 6.66B | 7.00B | 6.89B | 6.98B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.11B | 7.99B | 8.30B | 7.41B | 8.17B | 7.45B | 6.73B | 6.41B | 6.66B | 7.00B | 6.89B | 6.96B | 6.88B | 6.16B | 5.87B | 6.00B | 5.02B | 4.57B | 4.54B | 3.37B | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -41.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 98.00M | 88.00M | 74.00M | 44.00M | 28.00M | 0.00 | 90.00M | 0.00 | 0.00 |
| Operating Expenses | 10.63B | 8.18B | 8.37B | 7.54B | 8.70B | 7.47B | 6.75B | 6.39B | 6.70B | 7.52B | 7.31B | 7.16B | 6.98B | 6.25B | 5.94B | 6.05B | 5.05B | 4.27B | 4.63B | 3.37B | 2.35B |
| Cost & Expenses | 23.62B | 19.40B | 18.40B | 17.11B | 19.21B | 18.23B | 17.19B | 15.78B | 16.07B | 17.96B | 17.72B | 17.53B | 17.66B | 15.96B | 14.97B | 15.37B | 13.77B | 39.89B | 37.55B | 27.19B | 5.16B |
| Interest Income | 465.00M | 180.00M | 109.00M | 110.00M | 226.00M | 190.00M | 182.00M | 178.00M | 124.00M | 118.00M | 131.00M | 148.00M | 134.00M | 98.00M | 108.00M | 217.00M | 0.00 | 229.00M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.53B | 768.00M | 737.00M | 728.00M | 570.00M | 665.00M | 914.00M | 891.00M | 1.13B | 1.17B | 1.10B | 1.01B | 800.00M | 974.00M | 797.00M | 528.00M | 10.00M | 371.00M | 94.00M | 0.00 | 146.00M |
| Depreciation & Amortization | 1.40B | 1.19B | 998.00M | 981.00M | 964.00M | 989.00M | 875.00M | 743.00M | 754.00M | 889.00M | 882.00M | 898.00M | 98.00M | 932.00M | 853.00M | 44.00M | 748.00M | 658.00M | 527.00M | 370.00M | 0.00 |
| EBITDA | 13.37B | 13.79B | 14.17B | 12.92B | 11.95B | 12.58B | 12.46B | 11.71B | 11.47B | 12.67B | 14.48B | 14.85B | 14.48B | 12.19B | 10.94B | 11.09B | 9.64B | 9.23B | 8.26B | 6.57B | 2.95B |
| EBITDA Ratio | 38.02% | 42.88% | 44.81% | 44.26% | 40.34% | 41.60% | 43.06% | 43.31% | 42.71% | 44.10% | 47.11% | 47.31% | 43.89% | 45.12% | 43.63% | 40.69% | 43.57% | 18.08% | 18.44% | 19.67% | 36.36% |
| Operating Income | 12.70B | 12.54B | 13.08B | 11.72B | 11.06B | 11.34B | 11.50B | 10.82B | 10.69B | 12.24B | 13.82B | 13.95B | 13.33B | 11.20B | 10.04B | 10.25B | 8.87B | 8.37B | 7.74B | 6.20B | 2.95B |
| Operating Income Ratio | 36.10% | 39.49% | 41.64% | 40.84% | 37.10% | 38.26% | 40.01% | 40.53% | 39.90% | 41.11% | 44.28% | 44.45% | 42.87% | 41.16% | 40.10% | 39.87% | 38.92% | 17.34% | 17.08% | 18.56% | 36.36% |
| Total Other Income/Expenses | -2.09B | -773.00M | -695.00M | -751.00M | -1.04B | -605.00M | -855.00M | -797.00M | -971.00M | -947.00M | -995.00M | -959.00M | -810.00M | -876.00M | -797.00M | -311.00M | -49.00M | -124.00M | -94.00M | 17.00M | -179.00M |
| Income Before Tax | 10.61B | 11.77B | 12.38B | 10.97B | 10.02B | 10.73B | 10.65B | 10.02B | 9.72B | 10.76B | 12.52B | 12.99B | 12.53B | 10.32B | 9.24B | 9.94B | 8.86B | 8.23B | 7.64B | 6.21B | 2.77B |
| Income Before Tax Ratio | 30.16% | 37.06% | 39.42% | 38.23% | 33.62% | 36.22% | 37.04% | 37.54% | 36.28% | 36.13% | 40.11% | 41.39% | 40.30% | 37.94% | 36.92% | 38.66% | 38.88% | 17.05% | 16.87% | 18.61% | 34.16% |
| Income Tax Expense | 2.34B | 2.24B | 2.67B | 2.38B | 2.29B | 2.45B | 4.31B | 2.77B | 2.69B | 3.10B | 3.67B | 3.83B | 3.65B | 2.83B | 2.69B | 2.79B | 2.56B | 1.83B | 1.84B | 2.09B | 593.00M |
| Net Income | 7.79B | 9.05B | 9.11B | 8.06B | 7.19B | 7.91B | 6.04B | 6.97B | 6.87B | 7.49B | 8.58B | 8.80B | 8.59B | 7.26B | 6.34B | 6.89B | 6.03B | 6.15B | 5.62B | 3.98B | 2.23B |
| Net Income Ratio | 22.15% | 28.49% | 29.00% | 28.08% | 24.11% | 26.70% | 20.99% | 26.11% | 25.65% | 25.17% | 27.47% | 28.05% | 27.63% | 26.68% | 25.33% | 26.80% | 26.43% | 12.74% | 12.41% | 11.91% | 27.50% |
| EPS | 5.02 | 5.82 | 5.83 | 5.16 | 4.61 | 5.09 | 3.88 | 4.48 | 4.42 | 4.76 | 5.26 | 5.17 | 4.98 | 3.93 | 3.25 | 3.33 | 2.86 | 2.91 | 2.71 | 1.96 | 1.34 |
| EPS Diluted | 5.02 | 5.81 | 5.83 | 5.16 | 4.61 | 5.09 | 3.88 | 4.48 | 4.42 | 4.76 | 5.26 | 5.17 | 4.98 | 3.92 | 3.24 | 3.32 | 2.86 | 2.91 | 2.69 | 1.95 | 1.34 |
| Weighted Avg Shares Out | 1.55B | 1.55B | 1.56B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.55B | 1.57B | 1.62B | 1.69B | 1.73B | 1.84B | 1.94B | 2.07B | 2.11B | 2.11B | 2.07B | 2.03B | 0.00 |
| Weighted Avg Shares Out (Dil) | 1.55B | 1.55B | 1.56B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.55B | 1.57B | 1.62B | 1.69B | 1.73B | 1.84B | 1.95B | 2.08B | 2.11B | 2.11B | 2.09B | 2.04B | 0.00 |
Philip Morris to sell stake in pharma unit Vectura for $198 mln
Marlboro maker Philip Morris International's unit Vectura Fertin Pharma said on Tuesday it would sell its subsidiary Vectura Group to Molex Asia Holdings for 150 million pounds ($198.09 million).
Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex
STAMFORD, CT--(BUSINESS WIRE)--Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to...
Buy High-Quality Dividends Before It's Too Late - And 11 Picks Worth Considering
The Fed's rate cuts could trigger a rotation from bonds to dividend stocks, as investors seek alternatives for stable, attractive income. High-quality dividend stocks, particularly those offering inflation protection, are well-positioned to outperform in this shifting market. Investors should focus...
Broyhill's Q2 2024 Top Five Investments
Our top five investments—Avantor, Baxter, Fiserv, Nintendo, and Philip Morris—represented 50% of the equity portfolio, with mixed performance during the quarter. Avantor's shares rallied 26% in July after a strong earnings report, reaffirming full-year guidance and showing signs of industry...
Why Philip Morris (PM) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 of the best Stanley Druckenmiller stocks in 2024
Stanley Druckenmiller, the former money manager for George Soros, has one of the best track records in Wall Street. He has rarely had a negative year and has become a billionaire with a net worth of over $6.9 billion, according...
Strengthen Portfolio Defense With These Buy Rated Stocks: PPC, PM, OLLI
Stocks in the Zacks Consumer Staples sector carry a defensive nature, as these companies' products have an advantageous ability to generate consistent demand in the face of many economic situations.
Here's Why Philip Morris (PM) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Take the Zacks Approach to Beat the Markets: Philip Morris, IAMGOLD, Solventum in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Buy Low, Sell High, Get Paid To Wait (5 Easy Examples)
Buy Low, Sell High, Get Paid To Wait: Our simple investment philosophy focuses on purchasing assets at a discount to their intrinsic value. Key factors for maximizing profit include industry growth, management quality, and buying at a discount to value....
Source: https://incomestatements.info
Category: Stock Reports